Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
The Campbell's Company
CPB·Consumer Staples
F Avoid
Current$21.01
Sep 13, 2026

Campbell's owns durable food brands, strong cash generation and a possible cost-driven turnaround, but collapsing near-term earnings, persistent Snacks weakness and high leverage make its low valuation look more like a warning than a safety margin.

Score
49
Zai Lab Limited
ZLAB·Healthcare
D ★Strong Sell
Current$25.48
Nov 8, 2026

Zai Lab's promising global oncology pipeline and established China commercial platform offer substantial long-term opportunity, but declining product revenue, persistent cash burn, and equity dilution undermine its current investment appeal.

Score
48
The Macerich Company
MAC·Real Estate
D ★Strong Sell
Current$24.84
Nov 7, 2026

Macerich's premium shopping centers and improving leasing performance support an operating turnaround, but expensive valuation, substantial leverage, property-level mortgage defaults, and shareholder dilution undermine its investment appeal.

Score
48
Enphase Energy, Inc.
ENPH·Technology
D ★Strong Sell
Current$25.86
Oct 30, 2026

Enphase Energy retains valuable microinverter technology and long-term solar-storage growth opportunities, but contracting residential demand, weaker profitability, and uncertain recovery timing overshadow its current investment appeal.

Score
48
Enliven Therapeutics, Inc.
ELVN·Healthcare
D ★Strong Sell
Current$48.80
Nov 14, 2026

Enliven's promising relcobatinib program and substantial cash reserves support a potential CML breakthrough, but single-asset clinical dependence, significant dilution and a demanding valuation create substantial downside risk.

Score
47
Dyne Therapeutics, Inc.
DYN·Healthcare
D ★Strong Sell
Current$18.62
Nov 10, 2026

Dyne Therapeutics could establish valuable DMD and DM1 franchises through its differentiated FORCE platform, but pre-commercial losses, substantial dilution, and concentrated regulatory risks weaken the current investment case.

Score
47
Stellantis N.V.
STLA·Consumer Discretionary
D ★Strong Sell
Current$4.64
Oct 31, 2026

Stellantis could recover significant equity value through restructuring, stronger vehicle demand, and restored industrial cash flow, but persistent operating losses and substantial cash consumption make the turnaround exceptionally uncertain.

Score
47
KB Home
Current$48.01
Sep 27, 2026

KB Home's aggressive buybacks and Built to Order recovery could amplify a housing rebound, but weak affordability, compressed margins and rising leverage leave earnings too cyclical and uncertain for the current setup.

Score
47
Beam Therapeutics Inc.
BEAM·Healthcare
D ★Strong Sell
Current$27.02
Nov 10, 2026

Beam's successful pivotal base-editing data and diversified genetic medicine pipeline offer substantial long-term potential, but persistent cash burn, dilution, and uncertain commercialization undermine its current investment case.

Score
46
Under Armour, Inc.
UAA·Consumer Discretionary
D ★Strong Sell
Current$5.28
Nov 9, 2026

Under Armour offers potential upside from restructuring and a historically depressed sales valuation, but persistent revenue declines, weak margins, and negative free cash flow make a sustainable turnaround uncertain.

Score
46